Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
From a safety standpoint, retatrutide's known adverse effect profile from phase II trials includes: Nausea, vomiting, and diarrhoea (gastrointestinal effects common to GLP-1 receptor agonists) Reduced appetite and potential nutritional deficiencies with prolonged use Elevated heart rate observed in some trial participants Pancreatitis and gallbladder disease , which are recognised class cautions for GLP-1based therapies and should be considered in the context of retatrutide, although retatrutide-specific data remain limited Thyroid C-cell changes , observed in rodent studies with GLP-1 receptor agonists
Sequence details may vary by research reference
Wrinkles and fine lines
These are not the same thing, and understanding the difference changes how you evaluate the formulation
